rxstat › Shortages › Bosentan
Bosentan shortage status
Partial shortage
Source: Health Canada shortage reports · Updated Jul 9, 2026
Some Bosentan products are in shortage in Canada (2 of 12 reported products), while others remain available. Your pharmacy may be able to substitute an unaffected manufacturer. The latest estimate for affected products to return is Jun 30, 2027.
In shortage since
Nov 18, 2024
Est. full return
Jun 30, 2027
Talk to your pharmacist. Pharmacists can often substitute another manufacturer's version, a different strength, or (in most provinces) adapt or renew a prescription on the spot. Your free provincial health line is 811.
Reports by product
Active shortageNAT-BOSENTAN
125MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02467992 · since Nov 18, 2024, est. end Jun 30, 2027 · Other (Please describe in comments)
Active shortageNAT-BOSENTAN
62.5MG · TABLET · NATCO PHARMA (CANADA) INC
DIN 02467984 · since Nov 18, 2024, est. end Jun 30, 2027 · Other (Please describe in comments)
ResolvedTARO-BOSENTAN
125MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483149 · ended Aug 8, 2025 · Disruption of the manufacture of the drug.
ResolvedTARO-BOSENTAN
62.5MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483130 · ended Aug 8, 2025 · Disruption of the manufacture of the drug.
AvoidedSANDOZ BOSENTAN
125MG · TABLET · SANDOZ CANADA INCORPORATED
DIN 02386283 · ended Jan 30, 2021 · Disruption of the manufacture of the drug.
ResolvedTARO-BOSENTAN
125MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483149 · ended Jun 30, 2023 · Disruption of the manufacture of the drug.
ResolvedTARO-BOSENTAN
62.5MG · TABLET · TARO PHARMACEUTICALS INC
DIN 02483130 · ended Jun 30, 2023 · Disruption of the manufacture of the drug.
DiscontinuedPMS-BOSENTAN
125MG · TABLET · PHARMASCIENCE INC
DIN 02383020
DiscontinuedPMS-BOSENTAN
62.5MG · TABLET · PHARMASCIENCE INC
DIN 02383012
DiscontinuedAPO-BOSENTAN
125.0MG · TABLET · APOTEX INC
DIN 02399210
DiscontinuedAPO-BOSENTAN
62.5MG · TABLET · APOTEX INC
DIN 02399202
DiscontinuedAPO-BOSENTAN
125.0MG · TABLET · APOTEX INC
DIN 02399210
Showing 12 of 18 reports. All reports are on file with Health Canada.
What's happening
Bosentan is currently affected by 2 active shortage reports filed with Health Canada by NATCO PHARMA (CANADA) INC.
The reported cause is: other (please describe in comments). Manufacturers must report shortages, but end-date estimates are their own projections and often move.
If your usual product is affected, a pharmacist is the fastest route to a solution: they can dispense an unaffected manufacturer's equivalent when one exists, and in most provinces can adapt doses or substitute a therapeutic alternative without a new appointment.
Bosentan is classified under “OTHER ANTIHYPERTENSIVES” (ATC C02KX).
Recent changes
Common questions
When will Bosentan be back in stock in Canada?
The latest manufacturer estimate is Jun 30, 2027. Estimates are self-reported and often slip; this page updates automatically when they change.
Why is Bosentan in shortage?
See the reports above; manufacturers must state a reason (most commonly manufacturing disruption or a surge in demand) when filing with Health Canada.
What can my pharmacist do about it?
Often quite a lot: substitute an equivalent product from an unaffected manufacturer, adjust quantities, or in most provinces adapt or renew prescriptions on the spot. Call your pharmacy before visiting, and call 811 for free health advice.
All other antihypertensives shortage statuses →
Guides: what to do when your medication is in shortage · how to read shortage reports
Data reflects reports manufacturers are legally required to file with Health Canada, republished with per-drug aggregation by rxstat. Estimated end dates are supplied by manufacturers and frequently change. This page describes drug supply only and is not medical advice; never stop or switch a medication without speaking to your pharmacist or prescriber.